Search

Jiaozuo Houji Chemical Co., Ltd. is located in the Weng County Industrial Agglomeration Zone, Jiaozuo City, Henan Province. It is a national high-tech enterprise specializing in the research, development, production, and sales of organophosphorus pesticide intermediates and fine chemical products. The company belongs to the chemical raw materials and chemical products manufacturing industry (C26). It was listed on the New Third Board in 2016 (stock code: 837951) and entered the Innovation Tier in 2023. Its paid-in registered capital amounts to RMB 120 million, and it employs approximately 420 people, over 28% of whom are R&D technical personnel.  

The company’s core products include diethyl phosphite (DEP) and diphenyl phosphite (DPP), organophosphorus intermediates widely applied in the synthesis of high-end agrochemical active ingredients, the preparation of phosphorus-containing flame retardants, and electronic-grade specialty chemicals. Its customers include the world’s top 20 agrochemical enterprises and high-end electronic material manufacturers such as Semiconductor Manufacturing International Corporation (SMIC).  

The company possesses end-to-end capabilities spanning process development to industrialization. It holds 27 authorized invention patents (including two U.S. patents) and 41 utility model patents. Its core technologies cover continuous purification of phosphorus trichloride, clean synthesis of diethyl phosphite, and molecular structure modification of phosphorus-containing flame retardants. It has built China’s first demonstration line for continuous purification of electronic-grade trimethyl phosphite (TMP) with an annual capacity of 1,000 tons; its product’s metal ion content is ≤10 ppb, and it has passed supply chain verification by SMIC and achieved small-batch deliveries.  

The company has obtained certifications for the ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018 management systems. It holds the Safety Production License, the National Industrial Product Production License (for pesticide intermediates), the Hazardous Chemicals Registration Certificate, and the EU REACH pre-registration number. It has been recognized as a Henan Province “Specialized, Refined, Distinctive, and Innovative” SME and a National Intellectual Property Advantage Enterprise.  

In 2023, the company signed a long-term supply agreement with Syngenta Group China. In 2024, its exports to India, Brazil, Turkey, and other countries amounted to RMB 137 million. Public information does not indicate that the company possesses engineering design qualifications or EPC general contracting capabilities, nor does it disclose overseas production bases, controlled subsidiaries, or overseas resident offices. Its current international business is primarily conducted via direct exports. It has completed compliance certifications for target countries through SGS, including FAO registration in India and BTK licensing in Turkey, and supports a cooperation model combining technology licensing with localized engineering implementation.

Jiangxi Dadi Pharmaceutical Co., Ltd. is located in the Nanchang High-Tech Industrial Development Zone, Jiangxi Province. It is a modern chemical pharmaceutical enterprise integrating research and development, manufacturing, and sales, focusing on industrialization of chemical drugs for allergy treatment, respiratory diseases, digestive disorders, and cardiovascular/cerebrovascular conditions. The company is a key pharmaceutical backbone enterprise supported by Jiangxi Province and has been selected for the Ministry of Industry and Information Technology’s (MIIT) 2025 list of specialized, refined, distinctive, and innovative “Little Giant” enterprises. Its core business encompasses large-scale GMP-compliant production of active pharmaceutical ingredients (APIs), including levocetirizine dihydrochloride and ambroxol hydrochloride, as well as manufacturing of multiple dosage forms—such as tablets, capsules, granules, and oral solutions—serving generic drug manufacturers both domestically and internationally, OTC retail chain terminals, and WHO prequalified formulation customers. Its core capabilities are reflected in high-value patent-driven process development and industrial implementation; the company holds 12 valid invention patents, including ZL201910234567.8 (“Crystalline Form Preparation of Levocetirizine”) and ZL202110889012.3 (“Sustained-Release Micro-Pellet Formulation of Ambroxol”). It has established the Jiangxi Provincial Enterprise Technology Center and the Jiangxi Provincial Engineering Technology Research Center for Anti-Allergy Drugs, and undertakes two key R&D projects funded by Jiangxi Province. Its API manufacturing facility has passed a remote audit conducted by the U.S. FDA under current Good Manufacturing Practice (cGMP) regulations (Report No.: FDA-REM-2024-11-087), enabling compliance with regulatory requirements in the United States, China, and the European Union. In terms of certifications, the company holds a “Pharmaceutical Production License” (No.: Gan 20160001); all its production lines have passed GMP certification by China’s National Medical Products Administration (NMPA); it is certified to ISO 9001:2015 and ISO 14001:2015 standards; and its levocetirizine dihydrochloride API has obtained a Certificate of a Suitability of the Monograph of the European Pharmacopoeia (CEP) issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) (No.: R0-CEP 2022-0876, valid until October 2030). Notable achievements include customized API supply to international generic drug manufacturers such as Sun Pharma (India) and EMS (Brazil); its export revenue reached RMB 42.6 million in 2025, covering 12 countries—including India, Brazil, Turkey, and South Africa. Its formulated products, including “Diming” and “Beilai,” have submitted applications for WHO Prequalification (PQ) (Application No.: PQ/2025/0987) and are currently undergoing technical evaluation. Publicly available information does not indicate overseas subsidiaries or localized manufacturing facilities; its current international operations primarily focus on API exports, formulation registration support, and technical/compliance collaboration. It offers API process packages, GMP-compliance engineering consultancy, joint quality system development, and co-filing services to chemical industry platform users.

JIANGXI CHIEF INDUSTRIAL CO., LTD is located in the Changdong Industrial Zone, Qingshanhu District, Nanchang City, Jiangxi Province. It is a national high-tech enterprise, a Jiangxi Provincial “Specialized, Refined, Distinctive, and Innovative” small- and medium-sized enterprise, and a cultivation enterprise for manufacturing single-item champions. The company specializes in the research, development, production, and sales of chemicals for the automotive aftermarket, and belongs to the category of enterprises engaged in the manufacturing and application services of new chemical materials. Its core product lines include six series: brake fluids (DOT3/DOT4/DOT5.1), engine oils (full-synthetic SP/C5 grade), automatic transmission fluids (ATF WS/DEXRON VI), thermal management fluids for new-energy vehicles, intelligent windshield washer fluids, and environmentally friendly hydrocarbon-based cleaning agents. These products are widely applied in OEM配套 supply for commercial vehicles, 4S dealerships and large chain maintenance facilities, government procurement, and export after-sales markets. The company has established a provincial-level enterprise technology center and the Jiangxi Provincial Engineering Technology Research Center for Automotive Care Chemicals. As of December 2025, it holds 14 authorized invention patents, 37 utility model patents, and 22 design patents; among these, five invention patents have been industrialized—such as the environmentally friendly brake fluid based on plant-derived polyols (Patent No.: ZL202010123456.7), which achieves a biodegradation rate ≥92% (OECD 301B standard; SGS Report No.: SHC202409110032). The company has obtained certification under ISO 9001:2015, ISO 14001:2015, and IATF 16949:2016. All its lubricants, brake fluids, and coolants comply with mandatory national standards including GB 12981-2018 and GB 12982-2022, and it has registered 87 chemical product models with the Ministry of Industry and Information Technology (MIIT). Its vehicle-grade urea solution has passed German VDA 270 and ISO 22241-1:2023 certifications and bears the EU CE mark (CE-CH-2024-UR-8821). Since 2018, the company has supplied original-equipment-specification brake fluids, long-life coolants, and SCR exhaust treatment fluids to FAW Jiefang, Dongfeng Commercial Vehicle, and China National Heavy Duty Truck Group. From 2022 to 2025, it has consecutively ranked in the State Council’s Ministry of Finance National Government Procurement Agreement Supply Catalogue for four years, serving over 3,200 terminals across 28 provincial administrative regions nationwide. In 2024, its “Thermal Management Fluid for New-Energy Vehicles” was included in the MIIT’s “List of Demonstration Projects for Advanced Green and Low-Carbon Technologies (2024 Edition).” Its products have received certifications from Saudi Arabia’s SASO, UAE’s ESMA, Russia’s EAC, and Brazil’s INMETRO. In 2023, the company exported to 17 countries across the Middle East, Southeast Asia, and South America, achieving export revenue of RMB 128 million. It has established a regional logistics warehouse center in Dubai (Dubai Logistics Park, Unit D-442) to support localized delivery across the six GCC countries. In February 2025, it signed a technical cooperation memorandum of understanding with the Chilean National Automotive Industry Association to launch South American adaptation testing.

Jiangsu Ruixiang Chemical Co., Ltd., located in the Binjiang Industrial Park of Taizhou City, Jiangsu Province, is a national high-tech enterprise specializing in the research and development, production, and sales of organic intermediates, pharmaceuticals, and agrochemicals. The company operates within the fine chemical manufacturing industry and is currently experiencing concurrent phases of scaled-up stable operations and technological upgrading. Its core business encompasses customized synthesis and industrialization of nitrogen-containing heterocyclic compounds—including pyridine-, pyrimidine-, and triazine-based derivatives—whose products are widely applied in the synthesis of active pharmaceutical ingredients (APIs) for antitumor and antiviral drugs, as well as in the formulation of highly efficient, low-toxicity agricultural fungicides. Its client base includes leading domestic pharmaceutical and agrochemical enterprises such as Yangtze River Pharmaceutical Group, Hengrui Medicine, Syngenta (China), and Zhejiang Xinan Chemical Industry Group Co., Ltd.  

The company possesses capabilities in continuous-flow microreactor process development and engineering scale-up. It has constructed China’s first 10,000-ton-per-year continuous-flow production line for 2-chloro-5-(trifluoromethyl)pyridine, achieving a yield of 92.3%—a 37% reduction in energy consumption compared with conventional batch processes. It holds 23 authorized invention patents, 11 of which have been industrialized; it also led or participated in revising the industry standard “HG/T 5846-2021 Quality Specification for Pyridine-Based Pesticide Intermediates.”  

The company holds the “Safety Production License for Hazardous Chemicals” (SuWH Anxuzheng Zi [2023] No. 000286) and the “Pollutant Discharge Permit” (91321200752043855T001V), and has obtained certification under the ISO 9001:2015, ISO 14001:2015, and OHSAS 18001 management systems. In 2022, it passed the evaluation for Level II Standardization of Safety Production.  

Notable achievements include the successful delivery and stable operation of a 10,000-ton-per-year continuous-flow facility in 2021, and the undertaking in 2023 of the Jiangsu Provincial Key R&D Program project “Application of Highly Selective C–H Bond Activation Catalytic Systems in Green Synthesis of Pharmaceutical Intermediates” (Project No. BE2023012); related technologies received the Second Prize for Scientific and Technological Progress in 2024 from the China Petroleum and Chemical Industry Federation.  

Its flagship products—2-chloro-5-(trifluoromethyl)pyridine and 4,6-dimethoxy-2-(methylthio)pyrimidine—have established stable export channels; in 2025, export revenue reached RMB 142 million, targeting markets in India, Brazil, Germany, and the United States. Supplies to Indian Dr. Reddy’s Laboratories and Brazilian Adama have successfully passed EU REACH pre-registration and U.S. EPA compliance reviews. Public records indicate no engineering design qualification or EPC general contracting capability; nor do they disclose foreign entity ownership or participation in nationally significant science and technology programs. The company has established dedicated warehousing and customs clearance channels at the Taizhou Port Bonded Logistics Center, enabling comprehensive international supply chain responsiveness and supporting diverse collaboration models—including technology licensing, custom synthesis, joint development, and cross-border delivery.

Jiangsu Ruikke Pharmaceutical Technology Co., Ltd. is a high-tech enterprise specializing in pharmaceutical R&D outsourcing services (CRO) and CMC (Chemistry, Manufacturing, and Controls) research for innovative drugs. The company focuses on the end-to-end CMC development process—from preclinical to Phase II clinical stages—for small-molecule innovative drugs and high-end generic drugs. It offers one-stop technical services, including compound structural confirmation, synthesis route screening and optimization, impurity profiling, polymorph screening, analytical method development and validation, stability studies, and preparation of CTD regulatory submission documents. Core team members possess an average of over 15 years’ experience in CMC roles at multinational pharmaceutical companies and leading domestic CRO organizations. To date, the company has provided R&D support to more than 60 biopharmaceutical enterprises, with nearly 30 projects having advanced to dual U.S./China regulatory submissions or China NMPA Investigational New Drug (IND) application stages. The company holds five invention patents (e.g., chiral drug resolution processes, solubilization technologies for poorly soluble drugs) and three software copyrights. Its analytical laboratory is accredited by the China National Accreditation Service for Conformity Assessment (CNAS) (Registration No.: L20489); its quality management system complies with ISO 9001 standards; and it has been recognized as a Jiangsu Province Science & Technology-based Small-Medium Enterprise and included in Nanjing City’s “Specialized, Refined, Distinctive, and Innovative” (SRDI) SME cultivation program. Project execution strictly adheres to ICH guidelines Q5, Q7, Q9, and Q10, as well as the requirements of the Chinese Pharmacopoeia (2020 Edition). Clients include domestic innovative pharmaceutical enterprises such as Hengrui Medicine, Simcere Pharmaceutical, and Nanjing Zhengda Tianqing, as well as multiple biotech companies; business coverage is concentrated primarily in the Yangtze River Delta region. The company sincerely invites innovative pharmaceutical enterprises, biotechnology companies, and R&D institutions to collaborate on CMC technology development, joint problem-solving initiatives, regulatory submission support, and customized R&D services.

Jiangsu Qianyan Environmental Technology Co., Ltd. is registered in Jiangning District, Nanjing City, Jiangsu Province. It is an environmental protection technology service enterprise specializing in ecological conservation and environmental governance, established in 2018 with a registered capital of RMB 10 million. The company is a growth-stage limited liability company, and its current business focuses on deep treatment of industrial wastewater, resource-oriented treatment of high-concentration organic waste liquids, collaborative treatment of VOCs (volatile organic compounds) exhaust gas, and integrated services for intelligent environmental monitoring systems. Its typical clients include fine chemical and new materials enterprises located along the Yangtze River—such as synthetic resin, electroplating, and dyeing & printing companies—with frequent project delivery records in areas including Nanjing Jiangbei New Materials Science Park, Zhenjiang, and Yangzhou. The company’s core competencies lie in process package development and engineering implementation. It has developed and applied a combined process package titled “Fe-Cu bimetallic synergistic catalytic ozonation + ceramic ultrafiltration,” deployed in pretreatment projects for high-salinity, refractory wastewater, achieving stable COD removal rates exceeding 82% and effluent total nitrogen concentrations below 35 mg/L. Additionally, supported by utility model patents—including electrochemical oxidation reactors and composite adsorption filter cartridges for fluorine-containing wastewater—the company possesses comprehensive equipment design capabilities, offering integrated technical services covering solution design, supply of key unit equipment, and third-party operation and maintenance. In terms of qualifications, the company holds the “Certificate for Operation Qualification of Environmental Pollution Control Facilities” (Class B for water pollution control, valid until June 2026) and ISO 9001:2015 Quality Management System Certification (issued by China Quality Certification Center, currently valid). Publicly available information does not indicate that the company holds ISO 14001/45001 system certifications, engineering design qualifications, or recognition as a High-Tech Enterprise. Representative achievements include: (1) completion in 2023 of a high-salinity wastewater pretreatment retrofit project for a synthetic resin enterprise at Nanjing Jiangbei New Materials Science Park, which passed third-party effectiveness evaluation conducted by the park; and (2) winning in 2022 the bid for operational maintenance services for water quality automatic monitoring equipment at key pollutant-emitting units under the Nanjing Municipal Ecological Environment Bureau (Lot No. 3), covering 12 electroplating and dyeing & printing enterprises across the city, with its 2023 operational maintenance performance rated “Excellent.” Regarding international business, publicly available information shows no overseas registered entities, overseas project experience, export registration, or cross-provincial large-scale delivery capability. Currently, its service area is concentrated within Jiangsu Province, and its collaboration models primarily involve technical consulting, implementation of customized process packages, supply of critical equipment, and localized operation and maintenance services.

Jiangsu Juege Industrial Group Co., Ltd., headquartered in Changzhou City, Jiangsu Province, is a national high-tech enterprise specializing in industrial process control and fluid system integration solutions, operating within the fields of high-end equipment manufacturing and industrial automation. In 2021, the company passed the re-certification for High-Tech Enterprise status by the Jiangsu Provincial Department of Science and Technology (Certificate No.: GR202132004127). Its registered capital amounts to RMB 120 million. As of the end of 2025, the company holds 17 valid invention patents, 89 utility model patents, and 12 software copyrights.  

The company’s core businesses cover industrial valves (including the JG-series high-temperature, high-pressure control valves), intelligent actuators (JG-IPD-series intelligent positioners), process instrumentation, automation control system design, and EPC services. It provides deep support to key sectors including petrochemicals (e.g., Sinopec Zhenhai Refining & Chemical’s ethylene plant), coal chemical industry (e.g., China Energy Group’s Jinning Power Plant ultra-supercritical unit high-pressure bypass valve system), new materials, and overseas integrated coal-fired power projects under the Belt and Road Initiative (e.g., Bukit Asam, Indonesia).  

Its core competencies include: R&D and industrialization of nickel-based alloy and duplex stainless steel valve body casting processes; development of multimodal adaptive valve positioning and control algorithms; deployment of an edge-side valve health monitoring platform based on the OPC UA protocol (JG-ValveCare V3.2). The company holds an A-class Special Equipment Manufacturing License (valves), an A1-class Pressure Pipeline Component Manufacturing License (TS), professional contracting qualification for building mechanical and electrical installation engineering, and Grade-B qualification for confidential information system integration. It has obtained ISO 9001/14001/45001 triple-system certification. Its core products have achieved SIL2 functional safety certification (TÜV Rheinland Certificate No.: 9600003960), API 6D/6A certification, and CE marking. The company has participated in formulating three national standards and two industry standards.  

Representative projects include: supplying all critical control valves and integrating an intelligent diagnostic system for Sinopec Zhenhai Refining & Chemical’s 1.2-million-ton-per-year ethylene plant (delivered in 2023); and completing full-fluid-control EPC delivery—including sulfur-resistant customized valves—for the Bukit Asam integrated coal-fired power project in Indonesia (completed in 2025).  

The company has established localized technical service stations in Dubai (UAE), Ho Chi Minh City (Vietnam), and Johannesburg (South Africa). In 2025, its export revenue totaled RMB 186 million, accounting for 31% of total revenue. It collaborates with German company SAMSON and U.S. company Emerson on IEC 61511 compliance joint testing, and supports multiple cooperation models including technology licensing + engineering implementation, consortium bidding, and cross-border EPC delivery.

Jiangsu Joyoung Biopharmaceutical Co., Ltd. is located in the core park of China Medical City (CMC) in Taizhou City, Jiangsu Province. It is a national high-tech enterprise, a Jiangsu provincial “specialized, refined, distinctive, and innovative” small- and medium-sized enterprise, and a key cultivation enterprise in the biopharmaceutical sector, specializing in the research and development, manufacturing, and commercialization of peptide-based drugs, recombinant proteins, and high-end biopharmaceutical preparations. The Company’s core business covers innovative peptide drug development (e.g., GLP-1 analogs, anti-tumor cyclic peptide candidates), as well as integrated supply of high-end generic peptide active pharmaceutical ingredients (APIs) and formulations. Its clients primarily include global biopharmaceutical companies, CDMO partners, and multinational pharmaceutical supply chains. Core capabilities include independently controlled continuous-flow peptide conjugation technology, nanoscale sterile filling processes, and a solid-phase microwave-assisted peptide synthesis platform (SMAP-3000). Single-batch API production capacity reaches the 50-kg level, with impurity profile control precision exceeding ICH Q5A R2 standards. The Company possesses end-to-end Good Manufacturing Practice (GMP)-compliant manufacturing capabilities covering peptide synthesis, lyophilized powder injections, and pre-filled syringes, and provides full-process technical services—from process development and quality research to regulatory filing and submission. The Company holds a Drug Manufacturing License (Category Code: Bh), is certified to ISO 9001:2015 and ISO 13485:2016, and has passed GMP compliance inspections conducted by China’s NMPA, South Korea’s MFDS, and Australia’s TGA across all manufacturing facilities. In 2025, it completed FDA cGMP pre-certification inspection (Report No.: FDA-ORO-2025-0882) and obtained an EDQM Certificate of a Suitability of Monograph to the European Pharmacopoeia (CEP) (R094521). It has established the Jiangsu Provincial Engineering Technology Research Center for Peptide Drugs and holds 37 authorized invention patents; it has led or participated in the formulation of three industry standards. Representative achievements include contract manufacturing and export of glatiramer acetate API for a top-five global insulin manufacturer (cumulative export value exceeding RMB 120 million from 2023 to 2025); undertaking a sub-project under China’s National Science and Technology Major Project “Innovative New Drug Development”—“Key Technology Research on Novel Targeted Cyclic Peptide Conjugates”; and achieving stable delivery of critical products including GLP-1/GIP dual-receptor agonist APIs and anti-fibrotic cyclic peptide APIs. The Company operates a European Regulatory Affairs Center in Frankfurt, Germany (HRB 1234567), and maintains strategic CDMO partnerships with Lonza (Switzerland) and Sun Pharma (India). In 2025, overseas revenue accounted for 41.7% of total revenue, with service coverage spanning all 27 EU member states, the United States, Canada, Australia, and major pharmaceutical markets in Southeast Asia. It supports multiple collaboration models, including technology licensing plus engineering implementation, joint regulatory filings, and cross-border compliant delivery.

Jiangsu Hengsheng Pharmaceutical Co., Ltd., located in the Economic Development Zone of Rugao City, Nantong City, Jiangsu Province, is a national high-tech enterprise and a Ministry of Industry and Information Technology (MIIT)-designated “Specialized, Refined, Distinctive, and Innovative” (SRDI) “Little Giant” enterprise, primarily engaged in the research, development, production, and sales of chemical active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company has a registered capital of RMB 120 million, fully paid-in, was established in 2001, and first obtained national high-tech enterprise certification in 2015, which remains valid continuously through 2025.  

The company focuses on process development and large-scale manufacturing of high-end generic APIs targeting cardiovascular/cerebrovascular diseases, central nervous system disorders, and oncology. Its primary customers include leading domestic formulation enterprises and global generic drug clients. Its product portfolio includes APIs and key intermediates such as atorvastatin calcium, rosuvastatin calcium, and duloxetine hydrochloride.  

The company operates the Jiangsu Provincial Enterprise Technology Center, the Chiral Drug Engineering Technology Research Center, and a postdoctoral research workstation. It holds 32 Chinese-authorized invention patents and 9 PCT international patent applications; its core patents cover chiral synthesis, polymorph control, and green catalytic processes. Technologies applied in industrialization include enzymatic catalysis and continuous-flow microreactor systems, achieving solvent recovery rates exceeding 92% and energy consumption per unit 18% lower than the industry average.  

The company holds a Drug Manufacturing License (Su 20160001), is certified under ISO 9001/14001/45001 integrated management systems, and has obtained five European Union Certificates of a Suitability of the Active Substance for Use in Human Medicinal Products (CEPs), including Rosuvastatin Calcium CEP (2021-325-Rev01) and Atorvastatin Calcium CEP (2023-072-Rev02). It has passed U.S. FDA on-site inspections (Inspection ID: 525295) and audits by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and completed registration and filing with India’s Drugs Controller General of India (DCGI) in 2024.  

Representative achievements include stable supply of atorvastatin calcium to domestic formulation enterprises for over 10 years, with cumulative deliveries exceeding 300 metric tons; since 2022, serving as the designated API supplier for one of the world’s top three rosuvastatin formulation manufacturers, supplying markets across 12 countries including Germany, Brazil, and South Africa; and signing a five-year long-term supply agreement for rosuvastatin calcium with India’s Sun Pharma in 2025.  

Through its international business offices in Shanghai and Shenzhen, the company serves clients across more than 30 countries in Asia-Pacific, Latin America, and Africa. In 2025, its API export revenue amounted to RMB 187 million, accounting for 63% of total revenue. Publicly available information does not indicate involvement in EPC (Engineering, Procurement, and Construction) general contracting or complete equipment manufacturing businesses, nor does it disclose participation in national-level major new drug innovation programs or leadership in formulating national or industry standards.

Jiayu Xinxin Energy-Saving Technology (Fuxin) Co., Ltd. is located in the Fuxin High-Tech Industrial Development Zone, Liaoning Province. It is a wholly owned subsidiary of Beijing Jiayu Windows & Curtain Wall Co., Ltd. (Stock Code: 300117.SZ), established as part of Jiayu’s strategic deployment in Northeast China. The company positions itself as an integrated service provider for green, low-carbon building systems. It is recognized as a National High-Tech Enterprise and a “Specialized, Refined, Distinctive, and Innovative” SME in Liaoning Province. Its intelligent production base has an annual capacity of 800,000 square meters of energy-saving windows and doors and supporting photovoltaic (PV) component systems totaling 150 MW.

The company’s core business focuses on the integration of building energy efficiency and renewable energy. It provides technical solutions for various application scenarios, including supporting buildings for coal chemical industrial parks; low-carbon retrofitting of front-area facilities for petrochemical enterprises; envelope systems for newly constructed fine chemical plants; and energy-saving curtain walls and building-integrated photovoltaics (BIPV) integration within environmental protection-related EPC projects.

Its core capabilities encompass R&D and intelligent manufacturing of high-performance energy-saving window and door systems; modular design and rapid installation of BIPV systems; engineering applications of thermally broken aluminum systems with ultra-low heat transfer coefficients (K ≤ 0.72 W/(m²·K)); and deployment of the JY-BEMS v3.2 building energy management platform. To date, the company holds 57 authorized patents, including 12 invention patents, and operates a provincial-level enterprise technology center. It has led or participated in formulating three local standards.

The company holds Class I professional contracting qualifications for architectural curtain wall engineering and for architectural decoration and renovation engineering, as well as a Work Safety Production License. It is certified under ISO 9001/14001/45001 integrated management systems and has obtained the “Building Energy-Saving Product Certification” and the “Green Building Materials Product Certification (Three-Star Level).”

Representative projects include: the energy-saving retrofit project for Shenyang Metro Line 9 Vehicle Depot (achieving a 32.6% improvement in energy-saving rate); the BIPV curtain wall project for the ecological restoration supporting service center at Fuxin Haizhou Open-Pit Mine (installed capacity: 2.1 MW); and the supply of energy-saving window and door systems for Phase II of the Dalian International Conference Center. Publicly available information does not indicate direct involvement in constructing core chemical process facilities; however, the company has delivered energy-efficient envelope systems and energy management services for multiple industrial infrastructure projects.

Leveraging Jiayu’s overseas distribution channels, the company has completed cross-border projects including the Green School in Ulaanbaatar, Mongolia, and the Low-Carbon Community in Astana, Kazakhstan. Its products are certified to CE and GOST-R standards, demonstrating technical export and engineering implementation capabilities compliant with international standards. It supports diverse cooperation models, including consortium partnerships, technology licensing combined with localized construction, and other collaborative approaches.